Which inhibitor of the renin–angiotensin system should be used in chronic heart failure and acute myocardial infarction?
Circulation, 2004•Am Heart Assoc
puted placebo analysis). 21 In this analysis, losartan 50 mg once daily could not be shown
to be better than placebo. Concern that the dose of losartan was too low in this trial (and in
another trial in AMI) led to a further large outcome trial with losartan in CHF. The Heart
Failure Endpoint Evaluation With the Angiotensin II Antagonist Losartan (HEAAL) study is
comparing 50 mg of losartan once daily to 150 mg once daily in patients intolerant of an
ACE inhibitor. 22
to be better than placebo. Concern that the dose of losartan was too low in this trial (and in
another trial in AMI) led to a further large outcome trial with losartan in CHF. The Heart
Failure Endpoint Evaluation With the Angiotensin II Antagonist Losartan (HEAAL) study is
comparing 50 mg of losartan once daily to 150 mg once daily in patients intolerant of an
ACE inhibitor. 22
puted placebo analysis). 21 In this analysis, losartan 50 mg once daily could not be shown to be better than placebo. Concern that the dose of losartan was too low in this trial (and in another trial in AMI) led to a further large outcome trial with losartan in CHF. The Heart Failure Endpoint Evaluation With the Angiotensin II Antagonist Losartan (HEAAL) study is comparing 50 mg of losartan once daily to 150 mg once daily in patients intolerant of an ACE inhibitor. 22
Am Heart Assoc